TrialThe Lancet. Oncology2020

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

Ghassan K Abou-Alfa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.